Tonix Pharmaceuticals Holding Corp. (TNXP) Dividend History

Company News

• Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

  Tonix Pharmaceuticals has dosed the first patient in a Phase 2 trial evaluating TNX-102 SL for reducing acute stress reaction and acute stress disorder. The trial is sponsored by the University of North Carolina and supported by a grant from the U.S. Department of Defense. Topline results are expected in the second half of 2026.

  GlobeNewswire Inc.
• 2 Stocks Riding the Biotech Surge With Major Catalysts Ahead

  The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.

  Investing.com

  Featured Companies: LXEO
• Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

  Tonix Pharmaceuticals, a biopharmaceutical company, announced that its CEO will present at the Zacks SCR Life Sciences Virtual Investor Forum. The company's pipeline includes drug candidates for pain management, vaccines, and other therapeutic areas.

  GlobeNewswire Inc.
• Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight

  The increasing prevalence of chronic diseases is driving the demand for advanced and effective treatments, highlighting the need for AI-powered drug commercialization. Pharmaceutical companies are leveraging AI for personalized medicine, improving drug development and market strategy. Rising partnerships between technology providers and pharmaceutical firms are accelerating AI adoption, strengthening data analytics, and optimizing commercialization efforts.

  GlobeNewswire Inc.

  Featured Companies: CLVT ICLR TMO
• Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

  Tonix Pharmaceuticals, a biopharmaceutical company, announced that its CEO will present at the BIO CEO & Investor Conference. The company is focused on transforming therapies for pain management and vaccines, with a pipeline of development candidates targeting central nervous system disorders.

  GlobeNewswire Inc.